Lumida
/LNTH
⌘K
Lantheus Holdings Inc

Lantheus Holdings Inc

LNTH
$107.59USD↑+2.36%+2.48 today

MARKET CAP

7.0B

P/E (TTM)

18.0x

FWD P/E

19.2x

DAY RANGE

$103 – $108

52W RANGE

$47
$112

AI Summary

Stalk
Buy NowMedium

LNTH remains in Stage 2 advancing regime with a bullish medium-term bias. Price is pulling back into the rising 9/21/50 EMA support zone, offering a timely entry opportunity. Execution is recommended now on pullbacks into this support area. Key risks include overbought conditions near recent highs and failure to hold the EMAs, which would invalidate the bullish outlook.

  • ↑Alzheimer’s diagnostic market projected >$1.5B by 2030 drives MK6240 uptake.
  • ↑FDA approval for new F-18 PSMA PET agent expected, with 2027 revenue ramp.
  • ↓Polarify revenues expected to decline 8–10% in 2026 amid pricing pressure.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Lantheus Holdings, Inc. (NASDAQ: LNTH) specializes in developing and commercializing innovative diagnostic imaging solutions and therapeutic programs in nuclear medicine, particularly in oncology, neurology, and cardiology. The company is a leading player in the radiopharmaceutical sector, with a strong focus on products like Polarify, which addresses prostate cancer imaging, and NeuroSeq for Alzheimer’s imaging. Lantheus is positioned in a competitive environment marked by aggressive pricing dynamics and regulatory challenges, while it aims to leverage its product pipeline to create growth in evolving markets.

Bull says

  • ↑Alzheimer’s diagnostic market projected >$1.5B by 2030 drives MK6240 uptake.
  • ↑FDA approval for new F-18 PSMA PET agent expected, with 2027 revenue ramp.
  • ↑Q1 2026 free cash flow of $125M underscores strong operational efficiency.
  • ↑Authorized $400M share buyback reflects robust liquidity and capital discipline.
  • ↑Acquisitions of Evergreen and Life Molecular Imaging broaden radiopharma pipeline.
  • ↑Positive momentum and liquidity factors support near-term resilience.

Bear says

  • ↓Polarify revenues expected to decline 8–10% in 2026 amid pricing pressure.
  • ↓FDA CRL on LNTH-2501 manufacturing delays crucial product launch.
  • ↓Q1 2026 gross margin fell to 65.1% due to unfavorable pricing.
  • ↓Negative profitability factor signals weak return generation.
  • ↓PSMA PET competition intensifies, risking market share loss.
  • ↓Polarify revenue dropped 6.5% YoY to $240.9M in Q1 2026.

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 05-30-2026neutral

Transcript signals

Bull points

  • remain very excited about the long-term potential of PSMA-PET, with our addressable market potential in 2030 estimated to be $3.5 billion, affirming our optimism based on the Plovicto data and its approval with PSMA-4.
  • remain optimistic about the overall PSMA pet market and the long-term potential for Polarify, especially as we broaden the portfolio to be the go-to partner for hospitals and freestanding imaging centers.
  • we see very robust growth in the Alzheimer's marketplace as we monitor the trends of overall claims data related to Alzheimer's scans.

Bear points

  • We believe now is the right time to divest the spec business as we continue to focus on PET, radio diagnostics, microbubbles, and radiotherapeutic agents.
  • some of the smaller non-contracted accounts are growing higher than the overall market because they've been later adopters and are earlier in their adoption curves.
  • There has been a bit of what I would call stroke of the pen risk with them switching over to other agents
Read full transcript analysis ›